Immune Status at Presentation to Care Did Not Improve among Antiretroviral-Naive Persons from 1990 to 2006

Keruly, Jeanne C.; Moore, Richard D.
November 2007
Clinical Infectious Diseases;11/15/2007, Vol. 45 Issue 10, p1369
Academic Journal
Background. Human immunodeficiency virus (HIV) prevention initiatives to improve access to HIV services have increased over time. Despite this, >250,000 cases of HIV infection in the United States are undiagnosed, and many infected persons do not present for care until their HIV infection is advanced. Late presentation may increase the risk of HIV transmission and make HIV infection more difficult to treat effectively. With more effective HIV therapy, it was hoped that patients might present earlier in their disease course. Methods. To assess immune status and time of HIV diagnosis in patients who newly presented for care, we analyzed data for the period 1990-2006 from patients who were antiretroviral naive at presentation to the Johns Hopkins HIV Clinic in Baltimore, Maryland. We compared CD4+ cell count and time from HIV diagnosis at presentation by demographic characteristics at enrollment. Results. The median presenting CD4+ cell count decreased from 371 cells/mm3 during 1990-1994 to 276 cells/mm3 during 2003–2006 (P < .01 ) overall and decreased within individual demographic groups. There was also a P < .01 decrease in the median time from HIV diagnosis to presentation for care (271 days in 1990-1994 to 196 days in 2003-2006; ). Multivariate analysis revealed that, in addition to CD4+ cell count at presentation, male sex P < .01 was associated with lower CD4+ cell counts (-93 cells/mm3), as was black race (-71 cells/mm3) and older age (-20 cells/mm3 per 10 years). Conclusions. There has been a decrease in time from diagnosis of HIV infection to presentation for care, coupled with an increase in the severity of immunocompromise at time of presentation, over the past 16 years in Maryland. New strategies to provide earlier HIV testing and referral into care are urgently needed.


Related Articles

  • Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study. Murray, Daniel D.; Suzuki, Kazuo; Law, Matthew; Trebicka, Jonel; Neuhaus, Jacquie; Wentworth, Deborah; Johnson, Margaret; Vjecha, Michael J.; Kelleher, Anthony D.; Emery, Sean; null, null // PLoS ONE;10/14/2015, Vol. 10 Issue 10, p1 

    Introduction: The use of anti-retroviral therapy (ART) has dramatically reduced HIV-1 associated morbidity and mortality. However, HIV-1 infected individuals have increased rates of morbidity and mortality compared to the non-HIV-1 infected population and this appears to be related to end-organ...

  • Cytomegalovirus-Specific Immunity and Protection against Viremia and Disease in HIV-Infected Patients in the Era of Highly Active Antiretroviral Therapy. Weinberg, Adriana; Tierney, Camlin; Kendall, Michelle A.; Bosch, Ronald J.; Patterson-Bartlett, Julie; Erice, Alejo; Hirsch, Martin S.; Polsky, Bruce // Journal of Infectious Diseases;2/15/2006, Vol. 193 Issue 4, p488 

    To define the immune correlates of protection against cytomegalovirus (CMV) end-organ disease, CMV-specific interferon (IFN)-γ enzyme-linked immunospot (ELISPOT) and CD8+ and CD4+ intracellular IFN-γ synthesis assays were per- formed for subjects with CD4+ cell counts of ⩽50...

  • The Immunological Response after the Initiation of the Second Line Anti-Retroviral Therapy (ART) in HIV Patients. PILLAI, KEERTHI; RAMAPURAM, JOHN T.; ACHAPPA, BASAVAPRABHU; MADI, DEEPAK; CHOWTA, MUKTA N.; SATISH RAO, B.; MAHALINGAM, SOUNDARYA; UNNIKRISHNAN, B. // Journal of Clinical & Diagnostic Research;Sep2012, Vol. 6 Issue 7, p1171 

    Introduction: The treatment with the second line ART is initiated when the first line therapy fails. There is less experience with the immunologic response for the second-line ART for adults. Hence, this study was done to find out the immunological response after the initiation of the second...

  • Emtricitabine.  // AHFS Consumer Medication Information;Aug2020, p1 

    Emtricitabine is used with other medications to treat HIV infection in patients with or without AIDS. Emtricitabine is in a class of medications called nucleoside reverse transcriptase inhibitors (NRTIs). This medication works by slowing the spread of HIV in the body. Emtricitabine does not cure...

  • HIV-associated early gastric adenocarcinoma successfully cured with surgery, and followed over eight years. Manfredi, Roberto; Sabbatani, Sergio; Fasulo, Giovanni // International Journal of STD & AIDS;Jul2007, Vol. 18 Issue 7, p501 

    An extremely rare case report of HIV-associated gastric adenocarcinoma surgically treated in the year 1998 in a 37-year-old male patient already HIV positive for 10 years, with a complete post-surgery disease-free follow-up of eight years, is described. An international literature search allowed...

  • Early Virologic Failure in a Pilot Study Evaluating the Efficacy of Therapy Containing Once-Daily Abacavir, Lamivudine, and Tenofovir DF in Treatment-Naive HIV-Infected Patients. Khanlou, Homayoun; Yeh, Vivian; Guyer, Bill; Farthing, Charles // AIDS Patient Care & STDs;Mar2005, Vol. 19 Issue 3, p135 

    Previous investigational data using abacavir (ABC), lamuvidine (3TC), and zidovudine has suggested the possibility of triple nucleoside analogue reverse transcriptase inhibitors (NRTI) therapy as an option in the treatment of HIV infection. We performed a pilot study to assess the potency of...

  • South Africans Win Some, Lose Some. Houlton, Sarah // Pharmaceutical Executive;Oct2003, Vol. 23 Issue 10, p24 

    Reports that the South African government has approved the provision of antiretroviral drugs to HIV-positive South Africans. Funding by the Global Fund to Fight AIDS, Malaria and Tuberculosis of an AIDS program in KwaZulu Natal.

  • Three-Class Antiretroviral Resistance in a Patient with Acute HIV-1 Infection. Gentz, Mark; Levin, Todd P.; Klibanov, Olga M.; Feingold, Anat; Condoluci, David V. // AIDS Patient Care & STDs;Nov2006, Vol. 20 Issue 11, p741 

    Antiretroviral resistance in treatment-naïve patients with HIV-1 infection is on the rise in both resource-rich and resource-poor countries. We report a case of three-class primary antiretroviral resistance detected by a genotypic assay in a 19-year-old woman with acute HIV-1 infection. Her...

  • Treatment of HIV/AIDS: Do the Dilemmas Only Increase? Sande, Merle A.; Ronald, Allan // JAMA: Journal of the American Medical Association;7/14/2004, Vol. 292 Issue 2, p266 

    Presents an editorial on HIV/AIDS treatment and mentions articles in this issue of "JAMA". Guidelines set by the International AIDS Society-USA (IAS-USA) for HIV care reported in this issue; View that clinical trials using highly active antiretroviral therapy (HAART) should be redirected to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics